Getting patients started and supported with SAJAZIR (icatibant)
Cycle Vita is here to support your SAJAZIR patients with hereditary angioedema (HAE) with the product support they need to navigate their journey from diagnosis onwards.
Product support includes:
24/7 registered product support nurse
Field-based, with nation-wide coverage.
1-to-1 injection training
At home, clinic, or via video call.
Co-Pay Assistance Program*
For eligible patients this program will help cover the cost of insurance co-pays for SAJAZIR at 100%, up to the program maximum.
Quick Start Program*
Patients receive an immediate supply of medication while we support the finalization of the insurance paperwork.
We support eligible patients in the event of a transition between insurances by providing an uninterrupted supply of medicine.
Product support is easily accessible
Getting your patients started with SAJAZIR is straightforward, simply begin the enrollment process below.
Start your patient’s SAJAZIR enrollment here
Download, complete and fax a PDF
Patient Initiation Brochure
Let’s get started and connect you with the Cycle Vita team
*Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only.
Indication and Important Safety Information
SAJAZIR™ (Icatibant) injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.
Warnings and precautions: Given the potential for airway obstruction during acute laryngeal HAE attacks, patients should be advised to seek medical attention in an appropriate healthcare facility immediately in addition to treatment with SAJAZIR.
Adverse reactions: The most commonly reported adverse reactions were injection-site reactions, which occurred in almost all patients (97%) in clinical trials. These injection-site reactions included bruising, hematoma, burning, erythema, hypoesthesia, irritation, numbness, edema, pain, pressure sensation, pruritus, swelling, urticaria, and warmth.
Other common adverse reactions included pyrexia (4%), transaminase increase (4%), and dizziness (3%), as well as rash, nausea, and headache.
Drug interactions: Icatibant is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where SAJAZIR may attenuate the antihypertensive effect of ACE inhibitors. Clinical trials to date have excluded subjects taking ACE inhibitors.
Use in specific populations: Clinical studies of Icatibant included a limited number of subjects aged 65 and over. Elderly patients are likely to have increased systemic exposure. Reported clinical experience has not identified differences in efficacy and safety between elderly and younger patients.
Safety and effectiveness in patients below 18 years of age have not been established.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.
For more detailed information, please refer to the Full Prescribing Information.
To report SUSPECTED ADVERSE REACTIONS contact Cycle Pharmaceuticals at 1-800-836-4380, or the FDA at: 1-800-FDA-1088 or www.fda.gov/medwatch.